Literature DB >> 34766440

Left atrial unloading with an 8 mm septal cutting balloon to treat postcapillary pulmonary hypertension: a case report.

Fabrice Bauer1,2, Emmanuel Besnier2,3, Chadi Aludaat1, Romain Breil1, Nicolas Bettinger4, Charles Fauvel1,2, Véronique Wurtz3, Olivier Raitiere1, Nassima Si Belkacem1, Najime Bouhzam3.   

Abstract

We report the case of a 58-year-old female with severe postcapillary pulmonary hypertension (averaged mean pulmonary arterial pressure was 49 mmHg, pulmonary arterial wedge pressure 29 mmHg, and right atrial pressure 8 mmHg) due to heart failure with preserved ejection fraction. A left-to-right atrial shunt was created using an 8 mm cutting balloon, under transesophageal echocardiography guidance. Both pulmonary arterial and wedge pressure dramatically decreased after the procedure. Symptoms immediately improved and benefits were sustained at 6 months of follow-up. This case suggests that iatrogenic septal defect using a cutting balloon could be an option to treat symptomatic postcapillary pulmonary hypertension.
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Entities:  

Keywords:  Cutting balloon; Heart failure; Left atrium; Pulmonary hypertension

Mesh:

Year:  2021        PMID: 34766440      PMCID: PMC8787960          DOI: 10.1002/ehf2.13671

Source DB:  PubMed          Journal:  ESC Heart Fail        ISSN: 2055-5822


Introduction

Heart failure (HF) is a frequent syndrome associated with an increasing rate of admission to hospitals and a poor survival rate. With a prevalence varying from about 40–80% among registries, cut‐offs, phenotypes, and diagnostic tools, postcapillary pulmonary hypertension (PcPH) is one of the most frequent complications that worsens HF morbimortality. , Treating PcPH seems to be a serious option for HF patients at an early stage of the disease to improve their quality of life and to reduce symptoms mainly at exertion, as well as at advanced HF stages to reduce cardiovascular hospitalizations and death. , Several randomized control trials have been performed using either endothelin‐1 receptor antagonists or prostacyclin or phosphodiesterase type 5 inhibitors or soluble guanylate cyclase stimulators in PcPH patients; nevertheless, they failed to demonstrate routine use of vasodilation therapy for PcPH patients. At present, PcPH management is far from satisfactory mainly because research has focused on arterial vascular remodelling forgetting that PcPH is primarily related to an increase in left atrial (LA) pressure.

Case report

We report on the case of a 58‐year‐old female with a history of congenital aortic stenosis treated by aortic valve commissurotomy in 1972 then surgically converted to a Ross procedure in 2010 when her symptoms reoccurred. In 1998 and 2010, she underwent mastectomy, radiotherapy, and chemotherapy for bilateral breast cancer. In the context of chemotherapy, left ventricular (LV) ejection fraction was serially monitored. Her last examination reported biplane Simpson's rule LV ejection fraction above 50%, a 6 mm septal and posterior wall thickness, an early to late transmitral velocity E/A ratio of 2.9 with an averaged mitral septal, and lateral early tissue Doppler velocities e′ of 6.5 cm/s giving E/e′ ratio of 24.5, which is consistent with the diagnosis of type III diastolic dysfunction. LA volume index was 33 mL/m2, while right ventricular area was 21 cm2 with normal longitudinal systolic function (tricuspid annular plane systolic excursion = 17 mm and systolic tricuspid tissue velocity = 11 cm/s). Due to a refractory New York Heart Association (NYHA) functional class III, and suspected signs of PcPH evaluated by echocardiography (i.e. tricuspid regurgitation peak velocity of 3.9 m/s), she has been referred to our HF‐pulmonary hypertension centre. Transoesophageal echocardiography (TEE) ruled out significant mitral regurgitation, while a computed tomography pulmonary angiography disregarded pulmonary venous stenosis or other lung disease including chronic thromboembolic pulmonary hypertension. Stiff LA syndrome was excluded by invasive right heart catheterization, with no gradient found between pulmonary arterial wedge pressure (PAWP) and LV end‐diastolic pressure. A right heart catheterization was performed at rest. PAWP, mean pulmonary arterial pressure (mPAP), and right atrial pressure (RAP) were 29, 49, and 8 mmHg, respectively. Cardiac index averaged 2.8 L/min/m2, giving pulmonary vascular resistance (PVR) of 4.6 WU (Figure ). Finally, heart failure with preserved ejection fraction (HFpEF) related to valvular and radiation‐induced restrictive cardiomyopathy was the most likely cause of PcPH in this case.
Figure 1

Right heart catheterization. (A) Pulmonary arterial wedge pressure (PAWP), (B) pulmonary artery pressure, and (C) right atrial pressure (RAP) before and after opening the interatrial septum. All measurements were taken at end‐expiratory period. Note the significant drop in pulmonary artery pressure. Despite left‐to‐right atrial pressure and volume unloading, unexpected low RAP is observed in response to the left and downward shift of the right ventricular pressure‐volume loop. Red arrows indicate PAWP.

Right heart catheterization. (A) Pulmonary arterial wedge pressure (PAWP), (B) pulmonary artery pressure, and (C) right atrial pressure (RAP) before and after opening the interatrial septum. All measurements were taken at end‐expiratory period. Note the significant drop in pulmonary artery pressure. Despite left‐to‐right atrial pressure and volume unloading, unexpected low RAP is observed in response to the left and downward shift of the right ventricular pressure‐volume loop. Red arrows indicate PAWP. Due to an important PAWP to RAP pressure gradient, it was decided to create a left‐to‐right atrial shunt. The procedure took place under general anaesthesia with TEE and haemodynamic invasive monitoring, both from right heart catheterization and arterial blood pressure recording. With the biplane transoesophageal modality, a first transseptal puncture was performed in the mid‐fossa ovalis using an NRG‐radiofrequency transseptal needle interfacing with the Baylis Medical Radiofrequency Puncture Generator (RFP‐100‐115). By transesophageal echocardiography, the interatrial septal was 2 mm thickened. Prior to introducing the cutting balloon, a 3 mm balloon was inflated in the septal orifice. A 6 mm and then an 8 mm cutting balloon was positioned in the hole, inflated and deflated every 5 s, and rotated clockwise every 60° (Figure ). All materials were removed once the procedure was completed. TEE confirmed a 6/7 mm septal defect with a unidirectional left‐to‐right shunt (Figure ). Continuous‐wave Doppler interrogation revealed a drop in the left‐to‐right atrial pressure gradient, while the patient's post‐procedure right heart catheterization demonstrated an important pulmonary hypertension decrease when compared with the baseline (Figures and ).
Figure 2

Transoesophageal echo‐guided procedure. (A) Echo‐guided transseptal puncture in the mid‐fossa ovalis; (B) advancement of a Schwartz catheter in the left atrium; (C) stabilization of the stiff guidewire positioned into the left ventricle; and (D) a fossa ovalis circular section with 2 consecutive cutting balloon inflations, with a 60° clockwise rotation obtaining 6 radial cuts.

Figure 3

Left‐to‐right atrial shunt visualized in transoesophageal echocardiography. (A) Atrial septal defect by transoesophageal echocardiography with colour Doppler; (B) transatrial pressure gradient immediately after the first dilatation and (D) decreased at the end of the procedure; (C) the yellow arrow shows the residual 6 × 7 mm hole.

Transoesophageal echo‐guided procedure. (A) Echo‐guided transseptal puncture in the mid‐fossa ovalis; (B) advancement of a Schwartz catheter in the left atrium; (C) stabilization of the stiff guidewire positioned into the left ventricle; and (D) a fossa ovalis circular section with 2 consecutive cutting balloon inflations, with a 60° clockwise rotation obtaining 6 radial cuts. Left‐to‐right atrial shunt visualized in transoesophageal echocardiography. (A) Atrial septal defect by transoesophageal echocardiography with colour Doppler; (B) transatrial pressure gradient immediately after the first dilatation and (D) decreased at the end of the procedure; (C) the yellow arrow shows the residual 6 × 7 mm hole. At follow‐up, the shunt was unidirectional and persistent, and the patient reported functional improvement, while transthoracic echocardiography was consistent with LV diastolic function enhancement. Baseline, 1 month, and 6 months of follow‐up NYHA was 3, 2, and 2, respectively, while 6 min walking distance was 485, 486, and 450 m, respectively, and N‐terminal pro‐brain natriuretic peptide was 7273, 6160, and 5559 pg/mL, respectively.

Discussion

Patients with PcPH are defined as having both a PAWP > 15 mmHg and an mPAP > 20 mmHg. While PcPH—the most frequent form of pulmonary hypertension—negatively influences morbimortality, specific PcPH therapy does not exist. Treatment of symptomatic PcPH due to HFpEF is still challenging, focused on PVR decrease. Several randomized controlled trials have tested specific pulmonary vasodilation therapies without any proven benefit. Yet, the main target remains the passive backward transmission of elevated LV filling pressures to the pulmonary circulation. Unloading the LA with diuretics, or even better with LV assist devices, has proven to be the most efficient strategy for normalizing PVR, particularly in PcPH patients, as a bridge for heart transplantation. , , , Further, in the Lutembacher syndrome, patients with mitral stenosis are less symptomatic because of a left‐to‐right atrial shunt. Thus, clinicians are now reconsidering interventional procedures to normalize left‐sided filling pressures by creating an iatrogenic atrial septal defect. Permanent implants (e.g. the V‐wave, Corvia's InterAtrial Shunt Device, and Occlutech's Atrial Flow Regulator) and ‘leave nothing behind’ procedures (e.g. Venus NoYA, atrial balloon septostomy, radiofrequency, and Vardi endocardial septostomy) are used to open the interatrial septum, with orifices varying from 5.1 to 14 mm. All have been investigated in HFpEF patients with provokable high LV filling pressure during exercise but not to treat PcPH. Here, we report the first short‐term results of an iatrogenic atrial septal defect created to decrease LA pressure to treat symptomatic PcPH due to HFpEF. To reach a consistent drop in pulmonary arterial pressure, the patient was strictly selected for high LA pressure > 25 mmHg at rest, important left‐to‐right atrial pressure gradient (PAWP‐RAP) > 15 mmHg, and normal right ventricular function assessed by echocardiography. We used an 8 mm cutting balloon because in computer simulation, this diameter provides good results without overloading the right cavities. Furthermore, the larger the pressure gradient between both atria, the greater the PAWP‐RAP gradient reduction. Devices and ‘leave nothing behind’ procedures enabling a left‐to‐right atrial shunt are worth investigating in PcPH. To the best of our knowledge, no studies have explored this opportunity, likely because PcPH patients are often excluded from trials. ‘Leave nothing behind’ procedures like the cutting balloon have numerous advantages over other devices, including low cost, no risk of endocarditis, and, above all, the possibility for percutaneous closure in case of paradoxical embolism.

Conclusions

This case suggests that the use of an iatrogenic septal defect with a cutting balloon could be an efficient way to treat PcPH. Larger ongoing studies are needed to further investigate this possibility.

Permission

A completed consent form has been filled in by the patient discussed in this case report.

Conflict of interest

None declared.

Funding

None.
  13 in total

1.  The Atrial Flow Regulator device: expanding the field of interatrial shunting for treating heart failure patients.

Authors:  Leonardo Guimarães; David Del Val; Josep Rodés-Cabau
Journal:  EuroIntervention       Date:  2019-08-29       Impact factor: 6.534

2.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Sherif F Nagueh; Otto A Smiseth; Christopher P Appleton; Benjamin F Byrd; Hisham Dokainish; Thor Edvardsen; Frank A Flachskampf; Thierry C Gillebert; Allan L Klein; Patrizio Lancellotti; Paolo Marino; Jae K Oh; Bogdan Alexandru Popescu; Alan D Waggoner
Journal:  J Am Soc Echocardiogr       Date:  2016-04       Impact factor: 5.251

3.  Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in Heart Failure With Preserved Ejection Fraction.

Authors:  Jeffrey Wessler; David Kaye; Finn Gustafsson; Mark C Petrie; Gerd Hasenfuβ; Carolyn S P Lam; Barry A Borlaug; Jan Komtebedde; Ted Feldman; Sanjiv J Shah; Daniel Burkhoff
Journal:  Circ Heart Fail       Date:  2018-08       Impact factor: 8.790

4.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

5.  Left Ventricular Assist Devices in Pulmonary Hypertension Group 2 With Significantly Elevated Pulmonary Vascular Resistance: A Bridge to Cure.

Authors:  Ahmed M Selim; Lalit Wadhwani; Adam Burdorf; Eugenia Raichlin; Brian Lowes; Ronald Zolty
Journal:  Heart Lung Circ       Date:  2018-05-18       Impact factor: 2.975

6.  One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial.

Authors:  Sanjiv J Shah; Ted Feldman; Mark J Ricciardi; Rami Kahwash; Scott Lilly; Sheldon Litwin; Chris D Nielsen; Pim van der Harst; Elke Hoendermis; Martin Penicka; Jozef Bartunek; Peter S Fail; David M Kaye; Anthony Walton; Mark C Petrie; Niki Walker; Anupam Basuray; Steven Yakubov; Scott L Hummel; Stanley Chetcuti; Rhondalyn Forde-McLean; Howard C Herrmann; Daniel Burkhoff; Joseph M Massaro; John G F Cleland; Laura Mauri
Journal:  JAMA Cardiol       Date:  2018-10-01       Impact factor: 14.676

7.  Pulmonary hypertension due to left heart disease.

Authors:  Jean-Luc Vachiéry; Ryan J Tedford; Stephan Rosenkranz; Massimiliano Palazzini; Irene Lang; Marco Guazzi; Gerry Coghlan; Irina Chazova; Teresa De Marco
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

8.  Left atrial unloading with an 8 mm septal cutting balloon to treat postcapillary pulmonary hypertension: a case report.

Authors:  Fabrice Bauer; Emmanuel Besnier; Chadi Aludaat; Romain Breil; Nicolas Bettinger; Charles Fauvel; Véronique Wurtz; Olivier Raitiere; Nassima Si Belkacem; Najime Bouhzam
Journal:  ESC Heart Fail       Date:  2021-11-11

Review 9.  Predictors of hospitalisations for heart failure and mortality in patients with pulmonary hypertension associated with left heart disease: a systematic review.

Authors:  Anastase Dzudie; Andre Pascal Kengne; Friedrich Thienemann; Karen Sliwa
Journal:  BMJ Open       Date:  2014-07-10       Impact factor: 2.692

Review 10.  Pulmonary hypertension in chronic heart failure: definitions, advances, and unanswered issues.

Authors:  Emmanuelle Berthelot; Fabrice Bauer; Jean-Christophe Eicher; Erwan Flécher; Barnabas Gellen; Julien Guihaire; Damien Guijarro; Gérald Roul; Muriel Salvat; Christophe Tribouilloy; Florian Zores; Nicolas Lamblin; Pascal de Groote; Thibaud Damy
Journal:  ESC Heart Fail       Date:  2018-07-20
View more
  1 in total

1.  Left atrial unloading with an 8 mm septal cutting balloon to treat postcapillary pulmonary hypertension: a case report.

Authors:  Fabrice Bauer; Emmanuel Besnier; Chadi Aludaat; Romain Breil; Nicolas Bettinger; Charles Fauvel; Véronique Wurtz; Olivier Raitiere; Nassima Si Belkacem; Najime Bouhzam
Journal:  ESC Heart Fail       Date:  2021-11-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.